Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

126.48 +0.01 (+0.01%)
Streaming Delayed Price Updated: 10:23 AM EDT, Aug 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
48 49 Next >
Novartis' Kisqali Adds One More Year Of Survival Benefit In Breast Cancer Setting
 
Via Benzinga
VideoKrtoon Offers State Of The Art 2D Animation Services
Via Prodigy
No Early Relief for JW Therapeutics from Cancer Wonder Drug
Key Takeaways: JW Therapeutics prices its new cancer therapy at around a million yuan, with the high production costs hard to bring down.  Large-scale market expansion is not going to be easy  The... 
Via Benzinga
Appointment of Sachin Nanavati to PreveCeutical's Board of Directors
Vancouver, British Columbia--(Newsfile Corp. - September 6, 2022) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company"... 
Via Newsfile
SiO2 Materials Science Names Yves Steffen as Chief Executive Officer
SiO2 Materials Science today announced the Board of Directors has appointed Yves Steffen as CEO effective Aug. 1, 2022. 
Via Newswire.com
Top Financial Stories Thursday, September 1: Netflix Weighs Charging High Sum For Ads, Self Harm posts Grow On Twitter, California Fast-Food Bill Faces Industry Backlash...
Wall Street Journal 
Via Benzinga
Novartis Appoints Merck Executive As Research Head
 
Via Benzinga
NYSE:NVS Investor Alert: Investigation over Potential Wrongdoing at Novartis AG
San Diego, CA -- (SBWIRE) -- 08/30/2022 -- An investigation was announced over potential breaches of fiduciary duties by certain directors at Novartis AG. 
Via SBWire
Novartis' Scemblix Snags European Approval For Chronic Myeloid Leukemia
 
Via Benzinga
With Sandoz Spinoff, Novartis Slams Brakes On Huntington's Trial
Novartis AG (NYSE: NVS) suspended dosing in a Huntington's disease study because early signs of side effects were seen in some participants in the trial. 
Via Benzinga
Benzinga Before The Bell: Twitter Whistleblower Peiter Zatko To Depose Before Senate Panel, GameStop To Boost Employee Compensation To Drive Growth, California Proposes Total Ban On New Gasoline Car Sales By 2035 And Other Top Financial Stories Thursday,
Reuters Stuck By Chip Shortage, Stellantis Halts Production In Sochaux Plant 
Via Benzinga
Novartis To Spinoff Sandoz Business To Create #1 European Generics Company
 
Via Benzinga
Novartis' Lung Cancer Candidate Misses Primary Goal In Post Surgery Setting
 
Via Benzinga
Aerie Pharmaceuticals (NASDAQ: AERI) Enters into Agreement to be Acquired by Alcon (NYSE: ALC) for $770 Million
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) is engaged within the research, development and commercialization of ophthalmic therapies for the treatment of 
Via Spotlight Growth
Caribou's Blood Cancer Candidate Shows Response Rates Better Than Novartis,' This Analyst Writes
 
Via Benzinga
Emery Pharma Announces New Biologics Analytical Division
Supporting end-to-end research and development of large molecule drugs including, biologics, antibody-drug conjugates, biosimilars, and more 
Via Newswire.com
A Look Into Healthcare Sector Value Stocks
  Understanding Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base... 
Via Benzinga
The Most Expensive Drug From Novartis Associated With Two Deaths: Report
Two children with spinal muscular atrophy have died after receiving Novartis AG's (NYSE: NVS) Zolgensma, a one-time gene therapy, spotlighting its risks and questioning the safety of genetic medicines... 
Via Benzinga
This Nasal Spray For Eye Disease Stock Is 'Attractive', Has Potential 160% Upside
 
Via Benzinga
NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) Pioneering Innovative Hypertension Treatments
Via Investor Brand Network
Topics Intellectual Property
Deciphera's Cancer Drug Tops Pfizer's Sutent On Safety Front In Gastrointestinal Cancer
 
Via Benzinga
Laboratory Testing Leader Pace® Science and Technology Company Names Nisheet Gupta as New Chief Financial Officer
Experienced financial leader Nisheet Gupta has been appointed Executive Vice President and Chief Financial Officer of Twin Cities-based Pace®, a leader and innovator in testing, analysis, and... 
Via Newswire.com
Vizzia Technologies Named a Top 100 Healthcare Technology Company of 2022
Real-Time Data Analytics Service Provider Recognized for 2nd Consecutive Year 
Via Newswire.com
The Power of Science to Stop a Killer
Via Investor Brand Network
Smaller Biotechs May Pave Way For New Generation Of Therapeutics For Hard-to-Treat Neurological Disorders
An estimated 200 million Americans — more than 60% of the population — suffer from at least one neurological disorder. That includes dementia, strokes, migraines and other diseases or infections that... 
Via Benzinga
The Power of Science to Stop a Killer
NetworkNewsWire Editorial Coverage New York, NY – August 8, 2022 – Nearly half of all American adults suffer from hypertension (high blood pressure), often referred to as a silent killer. More than 114... 
Via FinancialNewsMedia
Voyager Therapeutics Prioritizes Pipeline With Cash Runway Into 2024
 
Via Benzinga
Death Cross Looms Over Novartis Investors
If history is any guide, there may be trouble ahead for shares of Novartis (NYSE:NVS). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock. 
Via Benzinga
Mark Cuban Says Americans Shouldn't Have To Pick Between Rent, Food Or Medicine
Famed billionaire, entrepreneur and Dallas Maverick’s owner Mark Cuban thinks Americans shouldn’t have to pick between necessities such as food, medicine or rent. And he’s provided a solution for at... 
Via Benzinga
Amphetamine Drug Market 2022: Industry Analysis, Size, Global Trends, Share, Growth, Opportunity and Forecast to 2028
Amphetamine Drug Market SWOT Analysis Including Key Players Pfizer, Novartis, Eli Lilly, GSK, Hisamitsu Pharmaceutical, Purdue Pharma 
Via SBWire
< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
48 49 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.